Profitelligence Profitelligence · Filing Ledger Open ILMN research →

Form 8-K · Current Report · Filed 2025-05-08

Illumina, Inc. Announces First Quarter 2025 Financial Results

On May 8, 2025, Illumina, Inc. issued a press release announcing its financial results for the first quarter ended March 30, 2025. The company did not provide specific financial details in the 8-K filing but mentioned the release for reference.

Filer
Illumina, Inc. ILMN · NASDAQ
Filed
Accession
0001110803-25-000044
CIK
0001110803
Signal
Low impactHealthcare

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 9.01

Financial Statements and Exhibits

No viable tag

Market reaction

Close before filing

$76.35

Next session

-0.8%

Since filing

+168.6%

Latest close

$205.10

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from ILMN reporting the same item, with the next session's move:

Exhibits (1)

About Illumina, Inc.

Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.

Exchange NASDAQ Industry Diagnostics & Research Company website ↗

Never miss another ILMN filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts